Silence Therapeutics has appointed Dr David Horn Solomon as its new CEO. David is an experienced public company biotech CEO, board member and biotech investor. He was the CEO of Zealand Pharma from 2008 to 2015 and earlier served as a faculty member at Columbia University’s College of Physicians and Surgeons in New York City. From 2003 to 2006, David headed healthcare investment at Carrot Capital Healthcare Ventures in New York. David is currently a member of the Board of Directors of TxCell and was earlier a member of the Boards at Onxeo SA and Promosome.
